FAT jabs may lower the risk of the UK’s biggest killer, according to a study of almost 400,000 adults with type 2 diabetes. The research, published in JAMA Neurology, examined two types of ...
SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.
Type 2 diabetes mellitus (T2DM) is a major public health challenge in India, with an estimated 101 million individuals ...
Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...
Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...
The study found that some people taking SGLT2 inhibitors developed a dangerous infection called Fournier gangrene. This ...
Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...
FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support ...
In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...
IgAN is a progressive, rare kidney disease in which the immune system attacks the kidneys, often causing glomerular ...
The global cardiometabolic drugs market is poised for significant expansion, with market size reaching USD 50 billion in 2021 and expected to surpass USD 70 billion by 2032. The market is projected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback